Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 490

Compelling investment opportunities in healthcare

Identifying and investing in the next big long-term structural growth trend is one way for investors to differentiate themselves in a competitive market.

Doing this is an integral part of our investing process at Munro Partners and we call these major growth trends areas of interests. Innovative health is one of Munro’s key areas of interest and one that is developing and advancing rapidly.

Health offers fertile ground for innovation across areas like diagnostics and patient care, genetic sequencing, virtual reality, and surgical robots.

The COVID pandemic brought specific investment opportunities in vaccines and treatment, but innovative health has been on a structural growth trend for over a decade on the back of several key drivers.

The drivers of healthcare innovation

There is a lot going on in the global healthcare landscape and we believe the resulting investment opportunities from this structural change are shaped by the below three trends.

1. Demographic change

Demographic change is having a real impact on healthcare as populations age across the developed world. Life expectancy has improved dramatically over the past 30 years. A baby born in Australia in 2020 can now expect to live to 81.2 years for a boy and 85.3 years for a girl, whereas in 1990 the equivalent figures were 73.9 and 80.1 years respectively.

The Baby Boomers, with higher expectations around their standard of living, are now between 58 and 76 years old.

A consequence of living longer is that many people end up with chronic conditions that need to be managed. For example, 46% of Australians aged over 65 suffer from two or more chronic conditions, compared with just 11% of those aged 15-44. Nearly half of all Australians aged over 75 have arthritis, and one in five has osteoporosis.

Not only do we have more diseases or medical conditions, but we are also expecting better care when we have them and are often prepared to pay for this superior care.

These demographic changes mean that disease prevention, treatment, and lifestyle management for the older members of society is a massive and growing subsector of the healthcare industry.

2. New technologies

Technology is making headway in healthcare, and companies across the spectrum - from start-up biotech pioneers to global pharmaceutical giants - are inventing new products and processes to assist in diagnosing, treating or curing diseases. More efficient healthcare provision is also a focus.

Predictive analytics in the field of artificial intelligence is also helping hospitals to better manage patient volumes and staff-to-patient ratios. And in surgery, micro robotics are being used in surgical treatments previously considered dangerous and invasive.

Innovations in the fields of genomics and gene therapy techniques are also important. These advances could be the start of a new era of personalised medicine as opposed to old-style generic treatment plans for all patients with the same diagnosis.

All of these innovations are huge and not only do they help in improving the health of everyone on the planet, they also offer a range of potential opportunities for long-term growth investors.

3. The rising cost of healthcare

This brings us to cost. Early-stage innovation technology is rarely cheap, and global spending on health climbed to US$8.5 trillion in 2019, or 9.8% of global gross domestic product (GDP), according to the World Health Organisation.

Unsurprisingly, health spending per capita in high-income countries was more than four times higher than in low-income countries, with the US healthcare system alone accounting for 42% of total global health spending.

There are therefore investment opportunities available in products, processes and systems that can reduce the cost of healthcare.

Lessons from Covid

As the pandemic spread around the world, the race to develop a successful vaccine to inoculate as many as possible began. But rather than pick a winner, in terms of what companies might emerge with the winning vaccine formula, at Munro Partners we decided to focus on the supply chain. We researched a wealth of opportunities and ended up focussing on companies in the biologics ecosystem which were critical in the development of the next generation mRNA (messenger ribonucleic acid) vaccines.

Biologic drugs are unique in that they are developed from cell culture media or living organisms rather than via a chemical synthesising process. Because of this, biologic drugs can specifically target the disease they’re designed to attack. This means they usually have a much higher efficacy and fewer side effects.

We looked to the supply chain for biologic drug companies and found investment opportunities in the companies supplying the consumable equipment needed by the vaccine producers, a strategy we saw as akin to investing in the picks and shovels that enabled the gold rush.

A stock story: Danaher Corporation

One such company is Danaher Corporation in the US. This is currently Munro's biggest position in innovative health and a company we were investing in long before Covid.

Danaher is a specialist in life science products, which make up over 50% of group profits, and is a major provider of the consumable products on which biologic drug developers rely. These products include filtration equipment and cell culture products, which provide a very high recurring revenue stream for the company. Danaher was also quick to develop Covid tests when the pandemic hit.

As biologic drugs take further market share from synthetically produced drugs, Danaher is in a good position to benefit. It has also made a number of strategic acquisitions including GE's bio-pharma business GE Healthcare Life Sciences, which it acquired in 2020 and renamed Cytivia. It is now a standalone operating company within Danaher's life sciences division.

To the future

In terms of innovative health, the long-term outlook will increasingly be about advances in cell and gene therapies, and genomics. Companies that supply those developing the vaccines and other therapies, like Danaher, are uniquely placed to benefit and where we see some of the biggest investment opportunities.

 

Jeremy Gibson is a partner and portfolio manager at Munro Partners. Munro is a specialist investment manager partner of GSFM Funds Management, a sponsor of Firstlinks. The information included in this article is provided for informational purposes only. Munro Partners do not represent that this information is accurate and complete, and it should not be relied upon as such. Any opinions expressed in this material reflect our judgment at this date, are subject to change and should not be relied upon as the basis of your investment decisions.

For more articles and papers from GSFM and partners, click here.

 

RELATED ARTICLES

The health care breakthrough that’s not an obesity drug

Investing in biotech and pharma

5 key investment themes for the next decade

banner

Most viewed in recent weeks

Australian house prices close in on world record

Sydney is set to become the world’s most expensive city for housing over the next 12 months, a new report shows. Our other major cities aren’t far behind unless there are major changes to improve housing affordability.

The case for the $3 million super tax

The Government's proposed tax has copped a lot of flack though I think it's a reasonable approach to improve the long-term sustainability of superannuation and the retirement income system. Here’s why.

Tariffs are a smokescreen to Trump's real endgame

Behind market volatility and tariff threats lies a deeper strategy. Trump’s real goal isn’t trade reform but managing America's massive debts, preserving bond market confidence, and preparing for potential QE.

The super tax and the defined benefits scandal

Australia's superannuation inequities date back to poor decisions made by Parliament two decades ago. If super for the wealthy needs resetting, so too does the defined benefits schemes for our public servants.

Meg on SMSFs: Withdrawing assets ahead of the $3m super tax

The super tax has caused an almighty scuffle, but for SMSFs impacted by the proposed tax, a big question remains: what should they do now? Here are ideas for those wanting to withdraw money from their SMSF.

Getting rich vs staying rich

Strategies to get rich versus stay rich are markedly different. Here is a look at the five main ways to get rich, including through work, business, investing and luck, as well as those that preserve wealth.

Latest Updates

SMSF strategies

Meg on SMSFs: Withdrawing assets ahead of the $3m super tax

The super tax has caused an almighty scuffle, but for SMSFs impacted by the proposed tax, a big question remains: what should they do now? Here are ideas for those wanting to withdraw money from their SMSF.

Superannuation

The huge cost of super tax concessions

The current net annual cost of superannuation tax subsidies is around $40 billion, growing to more than $110 billion by 2060. These subsidies have always been bad policy, representing a waste of taxpayers' money.

Planning

How to avoid inheritance fights

Inspired by the papal conclave, this explores how families can avoid post-death drama through honest conversations, better planning, and trial runs - so there are no surprises when it really matters.

Superannuation

Super contribution splitting

Super contribution splitting allows couples to divide before-tax contributions to super between spouses, maximizing savings. It’s not for everyone, but in the right circumstances, it can be a smart strategy worth exploring.

Economy

Trump vs Powell: Who will blink first?

The US economy faces an unprecedented clash in leadership styles, but the President and Fed Chair could both take a lesson from the other. Not least because the fiscal and monetary authorities need to work together.

Gold

Credit cuts, rising risks, and the case for gold

Shares trade at steep valuations despite higher risks of a recession. Amid doubts that a 60/40 portfolio can still provide enough protection through times of market stress, gold's record shines bright.

Investment strategies

Buffett acolyte warns passive investors of mediocre future returns

While Chris Bloomstan doesn't have the track record of his hero, it's impressive nonetheless. And he's recently warned that today has uncanny resemblances to the 1990s tech bubble and US returns are likely to be disappointing.

Sponsors

Alliances

© 2025 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.